Patent · US Active

Inhibition of AXL signaling in anti-metastatic therapy

US9074192B2 · kind B2 · utility

6Cited by

5References

7Claims

0Family size

Assignee

The Board of Trustees of the Leland Stanford Junior University · US

Inventors

Amato J. Giaccia · Stanford, US
Erinn Bruno Rankin · Waltham, US
Jennifer R. Cochran · Stanford, US
Douglas Jones · Newton, US
Mihalis Kariolis · South San Francisco, US
Katherine Fuh · Chesterfield, US
Yu Miao · Sunnyvale, US

Key dates

Filing date	Aug 27, 2012
Grant date	Jul 7, 2015
Priority date	—
Expiry date	Aug 27, 2032

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/7028
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.